Netherlands: Prilenia Therapeutics, a clinical stage biotech company, raised US$43m in Series B funding, bringing the total capital raised since its founding in September 2018 to US$133.5m. The round was led by Sands Capital with participation from Forbion and Morningside, Amplitude Ventures, Sectoral Asset Management, Talisman and the ALS Investment Fund. The company intends to…
Home Healthcare Markets International News Private finance: Asgard Therapeutics, Vensica Therapeutics, Sigrid Therapeutics, GlycoEra, Home Biosciences, illumigyn,...